The erythromycin breath test predicts the clearance of midazolam

[1]  I. Parashos,et al.  Drug pharmacokinetics and the carbon dioxide breath test , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  J. Bircher,et al.  Rate of drug metabolism in man measured by14CO2-breath analysis , 1978, European Journal of Clinical Pharmacology.

[3]  M. J. Eadie,et al.  The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.

[4]  J. Tredger,et al.  Importance of cytochrome P‐450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients , 1994, Hepatology.

[5]  T. Annesley,et al.  PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST , 1994, Transplantation.

[6]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[7]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam. , 1993, Clinical pharmacology and therapeutics.

[8]  X. J. Zhou,et al.  Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.

[9]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[10]  T. Annesley,et al.  Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients , 1992, Clinical pharmacology and therapeutics.

[11]  P. Watkins.  Drug metabolism by cytochromes P450 in the liver and small bowel. , 1992, Gastroenterology clinics of North America.

[12]  P. Watkins,et al.  The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease , 1992, Clinical pharmacology and therapeutics.

[13]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[14]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Kolars,et al.  The erythromycin breath test as a predictor of cyclosporine blood levels , 1990, Clinical pharmacology and therapeutics.

[16]  R. Amrein,et al.  Pharmacology of Dormicum (midazolam) and Anexate (flumazenil) , 1990, Acta anaesthesiologica Scandinavica. Supplementum.

[17]  C. Battel.  Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo , 1989 .

[18]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[19]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[20]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[21]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[22]  P. Srivastava,et al.  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. , 1989, The Journal of biological chemistry.

[23]  F. Guengerich.  Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.

[24]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[25]  A. Dickson,et al.  The verbal selective reminding test: preliminary data for healthy elderly. , 1987, Experimental aging research.

[26]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[27]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Schoeller,et al.  Clinical Utility of Breath Tests for the Assessment of Hepatic Function , 1983, Seminars in liver disease.

[29]  J. Dundee,et al.  Evaluation of midazolam as an intravenous induction agent , 1981, Anaesthesia.

[30]  P. McDonald,et al.  Intersubject and dose-related variability after intravenous administration of erythromycin. , 1980, British journal of clinical pharmacology.

[31]  J. Tredger,et al.  Importance of cytochrome P‐450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients , 1994, Hepatology.

[32]  T. Annesley,et al.  PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST , 1994, Transplantation.

[33]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[34]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam. , 1993, Clinical pharmacology and therapeutics.

[35]  X. J. Zhou,et al.  Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.

[36]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[37]  T. Annesley,et al.  Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients , 1992, Clinical pharmacology and therapeutics.

[38]  P. Watkins.  Drug metabolism by cytochromes P450 in the liver and small bowel. , 1992, Gastroenterology clinics of North America.

[39]  P. Watkins,et al.  The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease , 1992, Clinical pharmacology and therapeutics.

[40]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[41]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[42]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[43]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[44]  J. Kolars,et al.  The erythromycin breath test as a predictor of cyclosporine blood levels , 1990, Clinical pharmacology and therapeutics.

[45]  R. Amrein,et al.  Pharmacology of Dormicum (midazolam) and Anexate (flumazenil) , 1990, Acta anaesthesiologica Scandinavica. Supplementum.

[46]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[47]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[48]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[49]  D. Greenblatt,et al.  Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo , 1989, Clinical pharmacology and therapeutics.

[50]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[51]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[52]  P. Srivastava,et al.  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. , 1989, The Journal of biological chemistry.

[53]  F. Guengerich.  Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.

[54]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[55]  A. Dickson,et al.  The verbal selective reminding test: preliminary data for healthy elderly. , 1987, Experimental aging research.

[56]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[57]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Schoeller,et al.  Clinical Utility of Breath Tests for the Assessment of Hepatic Function , 1983, Seminars in liver disease.

[59]  J. Dundee,et al.  Evaluation of midazolam as an intravenous induction agent , 1981, Anaesthesia.

[60]  P. McDonald,et al.  Intersubject and dose-related variability after intravenous administration of erythromycin. , 1980, British journal of clinical pharmacology.

[61]  C. Puglisi,et al.  Determination of water soluble imidazo-1,4-benzodiazepines in blood by electron- capture gas--liquid chromatography and in urine by differential pulse polaragraphy. , 1978, Journal of Chromatography A.